An update from Eden Research ( (GB:EDEN) ) is now available.
Eden Research reported a 34% increase in revenue for 2024, reaching £4.3 million, driven by key authorizations and product developments. The company received significant regulatory approvals for its flagship product Mevalone® in the US, Spain, Germany, and Czechia, and launched Novellus+ in Mexico. Eden’s strategic advancements, including over 140 insecticide field trials and strengthened commercial teams, position it as a leader in the biopesticide industry. Despite an operating loss of £2.2 million, Eden’s commitment to sustainable agriculture and its recognition as ESG Company of the Year underscore its potential for future growth and industry leadership.
More about Eden Research
Eden Research is a UK-listed company specializing in biopesticides for sustainable agriculture. It develops biopesticide products and natural microencapsulation technologies for global crop protection, animal health, and consumer products industries. The company’s products, based on natural plant defense molecules, are used on high-value fruits and vegetables, offering performance comparable to conventional pesticides. Eden’s offerings include Mevalone®, Novellus®, Cedroz™, and Ecovelex™, with a focus on sustainable and environmentally friendly solutions.
YTD Price Performance: -24.05%
Average Trading Volume: 464,273
Technical Sentiment Signal: Buy
Current Market Cap: £16M
Find detailed analytics on EDEN stock on TipRanks’ Stock Analysis page.